Imatinib-induced eruptive nevi
Lamiaa Hamie1, Rayah Touma Sawaya2, Ossama Abbas1
1Department of Dermatology, American University of Beirut Medical Centre, Beirut, Lebanon.
Abstract:
Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of a variety of oncological conditions. It has been associated with a spectrum of pigmentary cutaneous side effects. Despite the well-known association of eruptive melanocytic nevi with the use of other tyrosine kinase inhibitors, this phenomenon has not been linked to the administration of imatinib. We present the first case of imatinib-induced eruptive nevi in an 18-year-old patient with acute lymphocytic leukaemia in remission.
Insights
Imatinib mesylate, a tyrosine kinase inhibitor, can cause skin side effects. This report details the first documented case of imatinib-induced eruptive nevi in a young patient with leukaemia.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Imatinib mesylate is a crucial tyrosine kinase inhibitor (TKI) for treating various cancers.
- Cutaneous side effects are common with imatinib mesylate, including pigmentary changes.
- Eruptive melanocytic nevi are known side effects of other TKIs but have not been previously linked to imatinib.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Mitogens and the Cell Cycle
Induced Pluripotent Stem Cells
Somatic...


